Literature DB >> 10946322

Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis.

T S Griffith1, R D Anderson, B L Davidson, R D Williams, T L Ratliff.   

Abstract

TNF-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily of cytokines that induces apoptosis in a variety of cancer cells. The results presented in this study demonstrate that introduction of the human TRAIL gene into TRAIL-sensitive tumor cells using an adenoviral vector leads to the rapid production and expression of TRAIL protein, and subsequent death of the tumor cells. Tumor cell death was mediated by an apoptotic mechanism, as evidenced by the activation of caspase-8, cleavage of poly(ADP-ribose) polymerase, binding of annexin V, and inhibition by caspase inhibitor zVAD-fmk. These results define a novel method of using TRAIL as an antitumor therapeutic, and suggest the potential use for an adenovirus-encoding TRAIL as a method of gene therapy for numerous cancer types in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10946322     DOI: 10.4049/jimmunol.165.5.2886

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

Review 1.  Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials.

Authors:  Jaesung Kim; Pyung-Hwan Kim; Sung Wan Kim; Chae-Ok Yun
Journal:  Biomaterials       Date:  2011-12-03       Impact factor: 12.479

2.  Enhanced effects of TRAIL-endostatin-based double-gene-radiotherapy on suppressing growth, promoting apoptosis and inducing cell cycle arrest in vascular endothelial cells.

Authors:  Yanbo Li; Caixia Guo; Zhicheng Wang; Pingsheng Gong; Zhiwei Sun; Shouliang Gong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-04-20

3.  Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC).

Authors:  F Yang; P Shi; X Xi; S Yi; H Li; Q Sun; M Sun
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 4.  Gene therapy for carcinoma of the breast.

Authors:  M A Stoff-Khalili; P Dall; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-06       Impact factor: 5.987

5.  Intratumoral versus intravenous gene therapy using a transcriptionally targeted viral vector in an orthotopic hepatocellular carcinoma rat model.

Authors:  Young Il Kim; Byeong-Cheol Ahn; John A Ronald; Regina Katzenberg; Abhinav Singh; Ramasamy Paulmurugan; Sunetra Ray; Sanjiv S Gambhir; Lawrence V Hofmann
Journal:  J Vasc Interv Radiol       Date:  2012-03-02       Impact factor: 3.464

6.  Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.

Authors:  Katherine A Murphy; Britnie R James; Yue Guan; Donald S Torry; Andrew Wilber; Thomas S Griffith
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 7.  TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

Authors:  Peter A Holoch; Thomas S Griffith
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

8.  NF-κB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL.

Authors:  Cigdem Aydin; Ahter D Sanlioglu; Atil Bisgin; Burcak Yoldas; Levent Dertsiz; Bahri Karacay; Thomas S Griffith; Salih Sanlioglu
Journal:  BMC Cancer       Date:  2010-10-27       Impact factor: 4.430

Review 9.  TRAIL gene therapy: from preclinical development to clinical application.

Authors:  Thomas S Griffith; Brittany Stokes; Tamara A Kucaba; James K Earel; Rebecca L VanOosten; Erik L Brincks; Lyse A Norian
Journal:  Curr Gene Ther       Date:  2009-02       Impact factor: 4.391

10.  Diet-induced obesity alters dendritic cell function in the presence and absence of tumor growth.

Authors:  Britnie R James; Ann Tomanek-Chalkley; Eric J Askeland; Tamara Kucaba; Thomas S Griffith; Lyse A Norian
Journal:  J Immunol       Date:  2012-06-27       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.